Gujarat Themis Biosyn Limited Stock Price Today (NSE: GUJTHEM)
Fundamental Score
Gujarat Themis Biosyn Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gujarat Themis Biosyn Limited share price today is ₹412.60, down 4.15% on NSE/BSE as of 16 September 2026. Gujarat Themis Biosyn Limited (GUJTHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.50K (Cr). The 52-week high for GUJTHEM share price is ₹479.00 and the 52-week low is ₹225.05. At a P/E ratio of 92.30x, GUJTHEM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 17.41% and a debt-to-equity ratio of 0.56.
Gujarat Themis Biosyn Limited Share Price Chart — NSE/BSE Historical Performance
Gujarat Themis Biosyn Limited share price chart: 23.32% return over the past month. 52-week high ₹479.00, 52-week low ₹225.05.
Gujarat Themis Biosyn Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹425.90 | ₹427.95 | ₹401.95 | ₹412.60 | 3.94L (Cr) | |
| ₹424.80 | ₹438.45 | ₹417.00 | ₹430.45 | 6.68L (Cr) | |
| ₹430.00 | ₹430.00 | ₹413.60 | ₹422.65 | 3.91L (Cr) | |
| ₹435.40 | ₹445.00 | ₹426.10 | ₹430.10 | 14.59L (Cr) | |
| ₹455.95 | ₹459.35 | ₹427.00 | ₹430.75 | 6.19L (Cr) | |
| ₹432.75 | ₹470.05 | ₹431.85 | ₹453.25 | 18.24L (Cr) | |
| ₹414.90 | ₹442.00 | ₹409.10 | ₹429.30 | 10.88L (Cr) | |
| ₹428.70 | ₹433.85 | ₹408.50 | ₹411.35 | 6.05L (Cr) | |
| ₹420.00 | ₹435.00 | ₹412.85 | ₹425.10 | 13.55L (Cr) | |
| ₹408.95 | ₹420.20 | ₹407.10 | ₹413.05 | 17.20L (Cr) |
Gujarat Themis Biosyn Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹423.90 | ₹470.05 | ₹401.95 | ₹412.60 | -2.67% | |
| ₹356.30 | ₹439.20 | ₹341.65 | ₹422.20 | +18.50% | |
| ₹398.00 | ₹408.70 | ₹346.50 | ₹358.05 | -10.04% | |
| ₹404.30 | ₹431.00 | ₹369.50 | ₹397.50 | -1.68% | |
| ₹365.00 | ₹441.20 | ₹336.90 | ₹404.30 | +10.77% | |
| ₹239.99 | ₹383.99 | ₹234.00 | ₹363.58 | +51.50% | |
| ₹285.00 | ₹306.80 | ₹225.05 | ₹226.90 | -20.39% | |
| ₹325.05 | ₹354.00 | ₹301.30 | ₹308.30 | -5.15% | |
| ₹441.65 | ₹445.00 | ₹305.00 | ₹323.10 | -26.84% | |
| ₹411.00 | ₹457.80 | ₹362.65 | ₹441.65 | +7.46% | |
| ₹465.10 | ₹471.80 | ₹397.70 | ₹407.60 | -12.36% | |
| ₹397.90 | ₹479.00 | ₹385.05 | ₹465.10 | +16.89% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gujarat Themis Biosyn Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gujarat Themis Biosyn Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GUJTHEM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (17.41%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.45%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (49.77%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (22.14%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (22.07%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (12.86% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Interest Coverage (22.06x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.53)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (70.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 92.30x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (18.10x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Negative Free Cash Flow (₹-117.12 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.97%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Gujarat Themis Biosyn Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gujarat Themis Biosyn Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gujarat Themis Biosyn LimitedGujarat Themis ...Selected✓ GUJTHEM • 506879 | 36.8/100 | ₹412.60₹413 | ₹4495.90₹4495.90 | 92.30Average 92.3 Average | 17.41%Good 17.41% Good | 18.45%Good 18.45% Good | 0.56Good 0.6 Good | 9.12%Good 9.12% Good | 12.86%Good 12.86% Good | 0.18% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9443.00₹9443 | ₹250239.50₹250239.50 | 85.68Average 85.7 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.20₹1370 | ₹110691.61₹110691.61 | 32.83Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1672.10₹1672 | ₹96212.63₹96212.63 | 26.13Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.80₹1146 | ₹95674.30₹95674.30 | 29.61Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price250239.50 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110691.61 Cr
Gujarat Themis Biosyn Limited PE Ratio History
Historical price-to-earnings ratio for GUJTHEM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.48 | ₹441.65 | 98.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Gujarat Themis Biosyn Limited Dividend History
Annual cash dividends paid by GUJTHEM — dividend yield 0.18%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.82 Cr |
| FY 2024 | ₹6.90 Cr |
| FY 2023 | ₹12.44 Cr |
| FY 2022 | ₹10.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Gujarat Themis Biosyn Limited Quarterly Performance
Latest quarterly metrics for GUJTHEM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
22.07%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
22.14%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.86%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
9.12%
Compounded annual net profit growth over 5 years
Gujarat Themis Biosyn Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GUJTHEM — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Gujarat Themis Biosyn Limited Financial Statements
Annual income statement, balance sheet and cash flow for Gujarat Themis Biosyn Limited (GUJTHEM) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Gujarat Themis Biosyn Limited
About GUJTHEM (Gujarat Themis Biosyn Limited)
Gujarat Themis Biosyn Ltd is a dynamic pharmaceutical company rooted in India, specializing in the meticulous manufacture of pharmaceuticals and crucial medicinal chemicals. Instea...d of merely producing drugs, Gujarat Themis Biosyn serves as a pivotal partner in the pharmaceutical supply chain, offering its extensive manufacturing capabilities on a job work basis to other entities operating within India. This model allows the company to maximize resource efficiency and contribute significantly to the wider availability of vital medicines throughout the region. By focusing on this area, Gujarat Themis Biosyn supports the healthcare ecosystem, enabling other companies to meet market demands without the burden of extensive in-house manufacturing infrastructure. The company’s product portfolio features an array of specialized pharmaceutical intermediates. Rifamycin-S takes center stage, a crucial component utilized in medications targeting a range of debilitating conditions. The portfolio includes Mycobacterium avium complex, leprosy, and Legionnaires’ disease. Additionally, they manufacture Rifamycin-O, essential for treating common ailments like traveler’s diarrhea and more complex disorders such as irritable bowel syndrome and hepatic encephalopathy. Gujarat Themis Biosyn also produces Lovastatin, a key ingredient in medicines aimed at managing cholesterol levels and promoting cardiovascular health. The company's dedication to producing these specialized ingredients highlights its role in contributing to both routine treatments and addressing critical health challenges. Established in 1981 and headquartered in Mumbai, Gujarat Themis Biosyn Ltd has cultivated a robust presence in the Indian pharmaceutical sector. Over the decades, the company has refined its manufacturing expertise and strengthened its commitment to quality and innovation. The company has positioned itself as a reliable source for bulk drug manufacturing and pharmaceutical intermediates, fostering trust and collaboration with its clients. The Mumbai headquarters serves as a central hub for overseeing its operations, guiding strategic decisions, and maintaining a steadfast commitment to improving health outcomes through pharmaceutical excellence.
Company Details
Key Leadership
GUJTHEM Share Price: Frequently Asked Questions
What is the current share price of Gujarat Themis Biosyn Limited?
Gujarat Themis Biosyn Limited (GUJTHEM) trades at ₹412.60 on NSE and BSE. Market cap ₹4.50K (Cr). Educational data only.
What is the P/E ratio of Gujarat Themis Biosyn Limited?
Gujarat Themis Biosyn Limited has a P/E of 92.30x vs industry average 34.89x.
What is the Bull Run score for Gujarat Themis Biosyn Limited?
Gujarat Themis Biosyn Limited has a Bull Run score of 36.8/100 based on 25+ financial parameters.
Does Gujarat Themis Biosyn Limited pay dividends?
Gujarat Themis Biosyn Limited has a dividend yield of 0.18%. Past dividends don't guarantee future payments.
What is the ROE of Gujarat Themis Biosyn Limited?
Gujarat Themis Biosyn Limited has ROE of 17.41%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gujarat Themis Biosyn Limited?
Gujarat Themis Biosyn Limited has debt-to-equity of 0.56.
Is Gujarat Themis Biosyn Limited a good investment?
Bull Run gives Gujarat Themis Biosyn Limited a score of 36.8/100. This is not investment advice — consult a SEBI-registered advisor.